

Robust T Cell Response Toward Spike, Membrane, and Nucleocapsid Proteins Not Associated with Recovery in Critical COVID-19 Patients

Cell Reports Medicine

1, 100092

DOI: [10.1016/j.xcrm.2020.100092](https://doi.org/10.1016/j.xcrm.2020.100092)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Approaches and Challenges in SARS-CoV-2 Vaccine Development. <i>Cell Host and Microbe</i> , 2020, 28, 364-370.	5.1	98
2	Epitope similarity cannot explain the pre-formed T cell immunity towards structural SARS-CoV-2 proteins. <i>Scientific Reports</i> , 2020, 10, 18995.	1.6	15
3	T cell immunity to SARS-CoV-2 following natural infection and vaccination. <i>Biochemical and Biophysical Research Communications</i> , 2021, 538, 211-217.	1.0	88
4	Lesions in the lungs of fatal corona virus disease Covid-19. <i>Annals of Anatomy</i> , 2021, 234, 151657.	1.0	10
5	COVID-19 and Solid Organ Transplantation: A Review Article. <i>Transplantation</i> , 2021, 105, 37-55.	0.5	241
8	Illuminating the immunopathology of SARS-CoV-2. <i>Cytometry Part B - Clinical Cytometry</i> , 2021, 100, 33-41.	0.7	11
9	Lessons in antiviral immunity. <i>Science</i> , 2021, 371, 464-465.	6.0	24
10	COVID-19: Current knowledge in clinical features, immunological responses, and vaccine development. <i>FASEB Journal</i> , 2021, 35, e21409.	0.2	71
11	COVID-19 herd immunity in the absence of a vaccine: an irresponsible approach. <i>Epidemiology and Health</i> , 2021, 43, e2021012.	0.8	8
12	SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates. <i>Npj Vaccines</i> , 2021, 6, 28.	2.9	507
13	Circulating CD4 T Cells Elicited by Endemic Coronaviruses Display Vast Disparities in Abundance and Functional Potential Linked to Antigen Specificity and Age. <i>Journal of Infectious Diseases</i> , 2021, 223, 1555-1563.	1.9	6
14	The Magnitude and Functionality of SARS-CoV-2 Reactive Cellular and Humoral Immunity in Transplant Population Is Similar to the General Population Despite Immunosuppression. <i>Transplantation</i> , 2021, 105, 2156-2164.	0.5	31
15	Most Japanese individuals are genetically predisposed to recognize an immunogenic protein fragment shared between COVID-19 and common cold coronaviruses. <i>F1000Research</i> , 2021, 10, 196.	0.8	7
16	Robust SARS-CoV-2-specific T cell immunity is maintained at 6 months following primary infection. <i>Nature Immunology</i> , 2021, 22, 620-626.	7.0	320
17	Longitudinal Assessment of Anti-Severe Acute Respiratory Syndrome Coronavirus 2 Immune Responses for Six Months Based on the Clinical Severity of Coronavirus Disease 2019. <i>Journal of Infectious Diseases</i> , 2021, 224, 754-763.	1.9	24
18	Bovine Coronavirus Immune Milk Against COVID-19. <i>Frontiers in Immunology</i> , 2021, 12, 637152.	2.2	16
19	Immune Responses to SARS CoV-2: A Scoping Review. <i>European Journal of Medical and Health Sciences</i> , 2021, 3, 10-16.	0.1	0
20	SARS-CoV-2-specific serological and functional T cell immune responses during acute and early COVID-19 convalescence in solid organ transplant patients. <i>American Journal of Transplantation</i> , 2021, 21, 2749-2761.	2.6	46

#	ARTICLE	IF	CITATIONS
22	Vaccinated and Convalescent Donorâ€Derived Severe Acute Respiratory Syndrome Coronavirus 2â€Specific T Cells as Adoptive Immunotherapy for High-Risk Coronavirus Disease 2019 Patients. <i>Clinical Infectious Diseases</i> , 2021, 73, 2073-2082.	2.9	15
23	Endothelial cell, myeloid, and adaptive immune responses in SARSâ€CoVâ€2 infection. <i>FASEB Journal</i> , 2021, 35, e21577.	0.2	13
25	Longitudinal profiling of respiratory and systemic immune responses reveals myeloid cell-driven lung inflammation in severe COVID-19. <i>Immunity</i> , 2021, 54, 797-814.e6.	6.6	272
26	The immune response to the novel coronavirus infection. <i>Journal of Clinical Practice</i> , 2021, 12, 33-40.	0.2	2
27	Adaptive immune responses to SARS-CoV-2. <i>Advanced Drug Delivery Reviews</i> , 2021, 172, 1-8.	6.6	6
28	Detection of SARSâ€CoVâ€2â€specific memory B cells to delineate longâ€term COVIDâ€19 immunity. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 2595-2599.	2.7	7
30	Identification and characterization of a SARS-CoV-2 specific CD8+ T cell response with immunodominant features. <i>Nature Communications</i> , 2021, 12, 2593.	5.8	94
31	Immune Response to COVID-19 mRNA Vaccineâ€A Pilot Study. <i>Vaccines</i> , 2021, 9, 488.	2.1	21
32	Deconvoluting the T Cell Response to SARS-CoV-2: Specificity Versus Chance and Cognate Cross-Reactivity. <i>Frontiers in Immunology</i> , 2021, 12, 635942.	2.2	20
33	Identification of cross-reactive CD8+ T cell receptors with high functional avidity to a SARS-CoV-2 immunodominant epitope and its natural mutant variants. <i>Genes and Diseases</i> , 2022, 9, 216-229.	1.5	28
34	Single dose of BNT162b2 mRNA vaccine against severe acute respiratory syndrome coronavirusâ€2 (SARSâ€CoVâ€2) induces neutralising antibody and polyfunctional Tâ€cell responses in patients with chronic myeloid leukaemia. <i>British Journal of Haematology</i> , 2021, 194, 999-1006.	1.2	55
35	Prospective Clinical, Virologic, and Immunologic Assessment of COVID-19 in Transplant Recipients. <i>Transplantation</i> , 2021, 105, 2175-2183.	0.5	19
36	The Safety and Immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 Vaccine in Hemodialysis Patients. <i>Frontiers in Immunology</i> , 2021, 12, 704773.	2.2	54
38	Detection of pre-existing SARS-CoV-2-reactive T cells in unexposed renal transplant patients. <i>Journal of Nephrology</i> , 2021, 34, 1025-1037.	0.9	6
39	How to interpret and use COVID-19 serology and immunology tests. <i>Clinical Microbiology and Infection</i> , 2021, 27, 981-986.	2.8	94
40	Distinctive features of SARS-CoV-2-specific T cells predict recovery from severe COVID-19. <i>Cell Reports</i> , 2021, 36, 109414.	2.9	75
41	Generation of glucocorticoid-resistant SARS-CoV-2 Tâ€cells for adoptive cell therapy. <i>Cell Reports</i> , 2021, 36, 109432.	2.9	24
42	Correspondence on â€SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune responseâ€. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e162-e162.	0.5	15

#	ARTICLE	IF	CITATIONS
43	What the HEC happens around the heart during COVID-19?. <i>Basic Research in Cardiology</i> , 2021, 116, 43.	2.5	0
44	Humoral and cellular immunity to SARS-CoV-2 vaccination in renal transplant versus dialysis patients: A prospective, multicenter observational study using mRNA-1273 or BNT162b2 mRNA vaccine. <i>Lancet Regional Health - Europe</i> , The, 2021, 9, 100178.	3.0	231
45	Aging and CMV Infection Affect Pre-existing SARS-CoV-2-Reactive CD8+ T Cells in Unexposed Individuals. <i>Frontiers in Aging</i> , 2021, 2, .	1.2	16
46	Two-Step In Vitro Model to Evaluate the Cellular Immune Response to SARS-CoV-2. <i>Cells</i> , 2021, 10, 2206.	1.8	4
47	Monitoring Specific IgM and IgG Production Among Severe COVID-19 Patients Using Qualitative and Quantitative Immunodiagnostic Assays: A Retrospective Cohort Study. <i>Frontiers in Immunology</i> , 2021, 12, 705441.	2.2	5
49	Identification of immune correlates of fatal outcomes in critically ill COVID-19 patients. <i>PLoS Pathogens</i> , 2021, 17, e1009804.	2.1	39
50	Adaptive immune responses to SARS-CoV-2 in recovered severe COVID-19 patients. <i>Journal of Clinical Virology</i> , 2021, 142, 104943.	1.6	9
51	The Immunology of SARS-CoV-2 Infection and Vaccines in Solid Organ Transplant Recipients. <i>Viruses</i> , 2021, 13, 1879.	1.5	16
52	SARS-CoV-2-specific T cells in infection and vaccination. <i>Cellular and Molecular Immunology</i> , 2021, 18, 2307-2312.	4.8	131
53	Severely ill patients with COVID-19 display impaired exhaustion features in SARS-CoV-2-reactive CD8 ⁺ T cells. <i>Science Immunology</i> , 2021, 6, .	5.6	185
59	Discordant neutralizing antibody and T cell responses in asymptomatic and mild SARS-CoV-2 infection. <i>Science Immunology</i> , 2020, 5, .	5.6	172
60	Long-Term SARS-CoV-2 Specific Immunity Is Affected by the Severity of Initial COVID-19 and Patient Age. <i>Journal of Clinical Medicine</i> , 2021, 10, 4606.	1.0	9
62	Immune Response in Myocardial Injury: In Situ Hybridization and Immunohistochemistry Techniques for SARS-CoV-2 Detection in COVID-19 Autopsies. <i>Frontiers in Molecular Biosciences</i> , 2021, 8, 658932.	1.6	5
63	Impaired Humoral but Substantial Cellular Immune Response to Variants of Concern B.1.1.7 and B.1.351 in Hemodialysis Patients after Vaccination with BNT162b2. <i>Journal of the American Society of Nephrology: JASN</i> , 2021, 32, 2725-2727.	3.0	15
64	Pediatric COVID-19 patients in South Brazil show abundant viral mRNA and strong specific anti-viral responses. <i>Nature Communications</i> , 2021, 12, 6844.	5.8	22
65	Robust and Persistent B- and T-Cell Responses after COVID-19 in Immunocompetent and Solid Organ Transplant Recipient Patients. <i>Viruses</i> , 2021, 13, 2261.	1.5	10
66	SARS-CoV-2 recombinant proteins stimulate distinct cellular and humoral immune response profiles in samples from COVID-19 convalescent patients. <i>Clinics</i> , 2021, 76, e3548.	0.6	3
67	SARS-CoV-2 memory B and T cell profiles in mild COVID-19 convalescent patients. <i>International Journal of Infectious Diseases</i> , 2022, 115, 208-214.	1.5	21

#	ARTICLE	IF	CITATIONS
69	Immune Response in Moderate to Critical Breakthrough COVID-19 Infection After mRNA Vaccination. <i>Frontiers in Immunology</i> , 2022, 13, 816220.	2.2	22
70	SARS-CoV-2-Specific T Cell Responses Are Stronger in Children With Multisystem Inflammatory Syndrome Compared to Children With Uncomplicated SARS-CoV-2 Infection. <i>Frontiers in Immunology</i> , 2021, 12, 793197.	2.2	14
72	Three Specific Potential Epitopes That Could Be Recognized by T Cells of Convalescent COVID-19 Patients Were Identified From Spike Protein. <i>Frontiers in Immunology</i> , 2022, 13, 752622.	2.2	2
74	Escape from recognition of SARS-CoV-2 variant spike epitopes but overall preservation of T cell immunity. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	77
75	Complement activation induces excessive T cell cytotoxicity in severe COVID-19. <i>Cell</i> , 2022, 185, 493-512.e25.	13.5	122
76	Guidelines for the use of flow cytometry and cell sorting in immunological studies (third edition). <i>European Journal of Immunology</i> , 2021, 51, 2708-3145.	1.6	198
77	Assessment of SARS-CoV-2 Immunity in Convalescent Children and Adolescents. <i>Frontiers in Immunology</i> , 2021, 12, 797919.	2.2	13
78	Dominant CD8+ T Cell Nucleocapsid Targeting in SARS-CoV-2 Infection and Broad Spike Targeting From Vaccination. <i>Frontiers in Immunology</i> , 2022, 13, 835830.	2.2	19
79	T cell responses to SARS-CoV-2 in humans and animals. <i>Journal of Microbiology</i> , 2022, 60, 276-289.	1.3	8
80	Limited Recognition of Highly Conserved Regions of SARS-CoV-2. <i>Microbiology Spectrum</i> , 2022, 10, e0278021.	1.2	5
81	Humoral and Cellular Immunogenicity and Safety of Five Different SARS-CoV-2 Vaccines in Patients With Autoimmune Rheumatic and Musculoskeletal Diseases in Remission or With Low Disease Activity and in Healthy Controls: A Single Center Study. <i>Frontiers in Immunology</i> , 2022, 13, 846248.	2.2	19
82	Longitudinal analysis of T cell receptor repertoires reveals shared patterns of antigen-specific response to SARS-CoV-2 infection. <i>JCI Insight</i> , 2022, 7, .	2.3	15
84	Assessment of changes in immune status linked to COVID-19 convalescent and its clinical severity in patients and uninfected exposed relatives. <i>Immunobiology</i> , 2022, 227, 152216.	0.8	2
85	Escape from recognition of SARS-CoV-2 Beta variant spike epitopes but overall preservation of T cell immunity.. <i>Science Translational Medicine</i> , 2021, , eabj6824.	5.8	11
86	Immunouniverse of SARS-CoV-2. <i>Immunological Medicine</i> , 2022, 45, 186-224.	1.4	8
87	Skewed Cellular Distribution and Low Activation of Functional T-Cell Responses in SARS-CoV-2 Non-Seroconvertors. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	2
88	The chimera of S1 and N proteins of SARS-CoV-2: can it be a potential vaccine candidate for COVID-19?. <i>Expert Review of Vaccines</i> , 2022, 21, 1071-1086.	2.0	3
89	Safety and Efficacy of Combined Intramuscular/Intranasal RAZI-COV PARS Vaccine Candidate Against SARS-CoV-2: A Preclinical Study in Several Animal Models. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	21

#	ARTICLE	IF	CITATIONS
91	Correlates of protection against <scp>SARS</scp>â€‹<scp>CoV</scp>â€‹ infection and COVIDâ€‹19 disease. Immunological Reviews, 2022, 310, 6-26.	2.8	138
92	Artificial intelligence and clinical data suggest the T cell mediated SARS-CoV-2 nonstructural protein intranasal vaccines for global COVID-19 immunity. Vaccine, 2022, , .	1.7	4
93	Time-dependent contraction of the SARS-CoV-2â€‹specific T-cell responses in convalescent individuals. , 2022, , .		0
94	Longitudinal Assessment of SARS-CoV-2-Specific T Cell Cytokine-Producing Responses for 1 Year Reveals Persistence of Multicytokine Proliferative Responses, with Greater Immunity Associated with Disease Severity. Journal of Virology, 2022, 96, .	1.5	19
95	Safety and efficacy of coronavirus diseaseâ€‹19 vaccines in chronic kidney disease patients under maintenance hemodialysis: A systematic review. Health Science Reports, 2022, 5, .	0.6	8
96	Hallmarks of Severe COVID-19 Pathogenesis: A Pas de Deux Between Viral and Host Factors. Frontiers in Immunology, 0, 13, .	2.2	10
97	mRNA BNT162b Vaccine Elicited Higher Antibody and CD4+ T-Cell Responses than Patients with Mild COVID-19. Microorganisms, 2022, 10, 1250.	1.6	2
98	Immunological memory to <scp>SARSâ€‹CoV</scp>â€‹ infection and <scp>COVID</scp>â€‹19 vaccines. Immunological Reviews, 2022, 310, 27-46.	2.8	137
99	Cellular Immune Response to BNT162b2 mRNA COVID-19 Vaccine in a Large Cohort of Healthcare Workers in a Tertiary Care University Hospital. Vaccines, 2022, 10, 1031.	2.1	6
100	The Robustness of Cellular Immunity Determines the Fate of SARS-CoV-2 Infection. Frontiers in Immunology, 0, 13, .	2.2	28
101	Immune responses to Sinopharm/<scp>BBIBPâ€‹CorV</scp> in individuals in Sri Lanka. Immunology, 2022, 167, 275-285.	2.0	8
102	Specific CD4+ T Cell Responses to Ancestral SARS-CoV-2 in Children Increase With Age and Show Cross-Reactivity to Beta Variant. Frontiers in Immunology, 0, 13, .	2.2	8
103	A Complementary Union of SARS-CoV2 Natural and Vaccine Induced Immune Responses. Frontiers in Immunology, 0, 13, .	2.2	8
104	Vaccination with a bacterial peptide conjugated to SARS-CoV-2 receptor-binding domain accelerates immunity and protects against COVID-19. IScience, 2022, 25, 104719.	1.9	0
105	Coordinated innate and T-cell immune responses in mild COVID-19 patients from household contacts of COVID-19 cases during the first pandemic wave. Frontiers in Immunology, 0, 13, .	2.2	12
106	SARS-CoV-2-reactive IFN-Î³-producing CD4+ and CD8+ T cells in blood do not correlate with clinical severity in unvaccinated critically ill COVID-19 patients. Scientific Reports, 2022, 12, .	1.6	2
107	COVID-19: Pathophysiology, Transmission, and Drug Development for Therapeutic Treatment and Vaccination Strategies. Current Pharmaceutical Design, 2022, 28, 2211-2233.	0.9	1
108	Vaccination in patients with kidney failure: lessons from COVID-19. Nature Reviews Nephrology, 2022, 18, 708-723.	4.1	46

#	ARTICLE	IF	CITATIONS
109	Evaluation of Hematologic Parameters in Patients with COVID-19 Following Mesenchymal Stem Cell Therapy. <i>DNA and Cell Biology</i> , 2022, 41, 768-777.	0.9	0
110	Accuracy of QuantiFERON SARS-CoV-2 research use only assay and characterization of the CD4+ and CD8+ T cell-SARS-CoV-2 response: comparison with a homemade interferon- γ release assay. <i>International Journal of Infectious Diseases</i> , 2022, 122, 841-849.	1.5	24
111	Different humoral but similar cellular responses of patients with autoimmune inflammatory rheumatic diseases under disease-modifying antirheumatic drugs after COVID-19 vaccination. <i>RMD Open</i> , 2022, 8, e002293.	1.8	9
112	High-resolution analysis of individual spike peptide-specific CD4+ T cell responses in vaccine recipients and COVID-19 patients. <i>Clinical and Translational Immunology</i> , 2022, 11, .	1.7	10
113	Measuring T-Cell Responses against SARS-CoV-2 Is of Utility for Disease and Vaccination Management. <i>Journal of Clinical Medicine</i> , 2022, 11, 5103.	1.0	5
115	Immune Determinants of Viral Clearance in Hospitalised COVID-19 Patients: Reduced Circulating Naïve CD4+ T Cell Counts Correspond with Delayed Viral Clearance. <i>Cells</i> , 2022, 11, 2743.	1.8	9
116	COVID-19 immunopathology: From acute diseases to chronic sequelae. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	24
117	SARS-CoV-2-specific humoral immunity in convalescent patients with mild COVID-19 is supported by CD4+ T-cell help and negatively correlated with Alphacoronavirus-specific antibody titer. <i>Immunology Letters</i> , 2022, 251-252, 38-46.	1.1	2
118	In vitro and in vivo evidence that the switch from calcineurin to mTOR inhibitors may be a strategy for immunosuppression in Epstein-Barr virus-associated post-transplant lymphoproliferative disorder. <i>Kidney International</i> , 2022, 102, 1392-1408.	2.6	4
119	COVID-19 Alpha Variant (B.1.1.7): Humoral, memory B and T cells in COVID-19 pediatric convalescents. <i>Pediatric Allergy and Immunology</i> , 2022, 33, .	1.1	1
120	Superior humoral immunity in vaccinated SARS-CoV-2 convalescence as compared to SARS-COV-2 infection or vaccination. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	9
121	The Flow Cytometry Study of Cellular Immunity in Rhesus Monkeys after Experimental Infection with SARS CoV 2 Virus. <i>Problemy Osobo Opasnykh Infektsii</i> , 2022, , 53-60.	0.2	0
122	Anti-SARS-CoV-2 antibody responses in convalescent plasma donors with varying severity of COVID-19 illness. <i>Vojnosanitetski Pregled</i> , 2022, 79, 1201-1208.	0.1	0
123	Adaptive Immunity to Viruses: What Did We Learn from SARS-CoV-2 Infection?. <i>International Journal of Molecular Sciences</i> , 2022, 23, 13951.	1.8	5
124	Association between SARS-CoV-2 RNAemia and dysregulated immune response in acutely ill hospitalized COVID-19 patients. <i>Scientific Reports</i> , 2022, 12, .	1.6	9
125	Longitudinal antibody titer, avidity, and neutralizing responses after SARS-CoV-2 infection. <i>Heliyon</i> , 2022, 8, e11676.	1.4	4
126	Autoimmunity and Immunodeficiency in Severe SARS-CoV-2 Infection and Prolonged COVID-19. <i>Current Issues in Molecular Biology</i> , 2023, 45, 33-50.	1.0	14
127	Clonal diversity predicts persistence of SARS-CoV-2 epitope-specific T-cell response. <i>Communications Biology</i> , 2022, 5, .	2.0	5

#	ARTICLE	IF	CITATIONS
128	Cellular and humoral immune response to the fourth Pfizer-BioNTech COVID-19 vaccine dose in individuals aged 60 years and older. <i>Vaccine</i> , 2023, 41, 914-921.	1.7	3
129	The role of T cell immunity in COVID-19. , 2023, , 129-140.		0
130	Kidney Transplant Patients Generate Varicella Zoster-reactive T-cell and Humoral Immunity Following Protein-based Varicella Zoster Vaccination. <i>Transplantation</i> , 2023, 107, e58-e59.	0.5	0
131	A Highly Sensitive Flow Cytometric Approach to Detect Rare Antigen-Specific T Cells: Development and Comparison to Standard Monitoring Tools. <i>Cancers</i> , 2023, 15, 574.	1.7	0
132	SARS-CoV-2 nucleocapsid: Biological functions and implication for disease diagnosis and vaccine design. <i>Reviews in Medical Virology</i> , 2023, 33, .	3.9	7
133	Assesment of specific T-cell immunity to SARS-CoV-2 virus antigens in COVID-19 reconvalescents. <i>Voprosy Virusologii</i> , 2023, 67, 527-537.	0.1	1
134	SARS-CoV-2 Vaccine-Induced T-Cell Response after Three Doses in People Living with HIV on Antiretroviral Therapy Compared to Seronegative Controls (CTN 328 COVAXHIV Study). <i>Viruses</i> , 2023, 15, 575.	1.5	5
136	Long term SARS-CoV-2-specific cellular immunity after COVID-19 in liver transplant recipients. <i>Journal of Microbiology, Immunology and Infection</i> , 2023, 56, 526-536.	1.5	2
137	Limited induction of polyfunctional lung-resident memory T cells against SARS-CoV-2 by mRNA vaccination compared to infection. <i>Nature Communications</i> , 2023, 14, .	5.8	8
138	Impaired SARS-CoV-2 specific T-cell response in patients with severe COVID-19. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	2